Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Possis Medical, Inc.

This article was originally published in The Gray Sheet

Executive Summary

Files registration with the Securities and Exchange Commission for 1,552,500 shares of common stock to be sold at 5-3/4 per share. Of the proceeds, 50% will fund R&D of additional uses of the company's three key products, the AngioJet thrombectomy system, the Perma-Flow graft, and the Perma-Seal graft. The products are all in human clinical trials in the U.S. and in "early stage sales" in Europe and Japan. An additional 25% of the proceeds will fund the clinical trials for the key products, and approximately $500,000 will be used for repayment of a loan. The offering includes 202,500 shares to cover over-allotments for underwriter John G. Kinnard and Company, Inc. Possis plans to issue warrants to the underwriter to purchase 120,000 additional shares. After the offering, 9.7 mil. shares of common stock will be outstanding

You may also be interested in...



Will MDR Delays Create Roadblocks For Companion Diagnostics Regulation?

Companion diagnostics are needed increasingly by pharma companies to justify the safety and effectiveness of their products. With specific first-time EU regulation of these products within sight – and urgently needed is there a risk of delays to these products being able to demonstrate compliance?

India Rare Disease Policy Proposes Crowdfunding But Patients Feel Let Down

Draft policy moots crowdfunding for high-cost rare diseases alongside financial support for those "amenable to one-time treatment" but falls way short of some patient groups' expectations.

India’s Hilleman Plans ‘Affordable’ Vaccine Against Group B Strep

India’s Hilleman Laboratories says it’s aiming to develop an affordable vaccine that will target pregnant women in low- and middle-income countries to prevent Group B Streptococcus, a potentially fatal infection passed to babies during childbirth.

UsernamePublicRestriction

Register

MT002639

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel